[{"id":"4bf8a0e4-ad61-4bd3-8b19-15b271d96a0b","acronym":"D9750C00001","url":"https://clinicaltrials.gov/study/NCT06005493","created_at":"2023-08-22T15:08:52.377Z","updated_at":"2025-02-25T14:10:00.557Z","phase":"Phase 1/2","brief_title":"Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT06005493 - D9750C00001","lead_sponsor":"AstraZeneca","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive • CLDN1 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive • CLDN1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD5863"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 07/11/2023","start_date":" 07/11/2023","primary_txt":" Primary completion: 12/16/2026","primary_completion_date":" 12/16/2026","study_txt":" Completion: 12/16/2026","study_completion_date":" 12/16/2026","last_update_posted":"2025-02-18"},{"id":"56fa4122-48b0-496d-9b08-3036a6a23a21","acronym":"TACTIC-3","url":"https://clinicaltrials.gov/study/NCT05862324","created_at":"2023-05-17T14:05:21.313Z","updated_at":"2025-02-25T14:42:02.177Z","phase":"Phase 1/2","brief_title":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)","source_id_and_acronym":"NCT05862324 - TACTIC-3","lead_sponsor":"Triumvira Immunologics, Inc.","biomarkers":" EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation","tags":["EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 113","initiation":"Initiation: 08/23/2023","start_date":" 08/23/2023","primary_txt":" Primary completion: 08/01/2027","primary_completion_date":" 08/01/2027","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2025-02-14"},{"id":"6bcd23c9-26d4-4ce6-8abc-592de885dbb3","acronym":"TWINPEAK","url":"https://clinicaltrials.gov/study/NCT05482893","created_at":"2022-08-01T14:54:48.052Z","updated_at":"2025-02-25T16:18:00.073Z","phase":"Phase 1/2","brief_title":"Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study)","source_id_and_acronym":"NCT05482893 - TWINPEAK","lead_sponsor":"Phanes Therapeutics","biomarkers":" CLDN18","pipe":" | ","alterations":" HER-2 overexpression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • 5-fluorouracil • capecitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • spevatamig (PT886)"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 03/15/2023","start_date":" 03/15/2023","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2025-01-31"},{"id":"6cde80ee-7854-4076-a153-49db79a1f8a8","acronym":"8951-CL-5201","url":"https://clinicaltrials.gov/study/NCT03816163","created_at":"2021-01-18T18:51:16.508Z","updated_at":"2025-02-25T17:24:01.354Z","phase":"Phase 2","brief_title":"A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer","source_id_and_acronym":"NCT03816163 - 8951-CL-5201","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • albumin-bound paclitaxel • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 393","initiation":"Initiation: 03/15/2019","start_date":" 03/15/2019","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-01-31"},{"id":"22c483bd-8d57-4189-a689-237ee22d7ecc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06767449","created_at":"2025-02-26T07:14:39.447Z","updated_at":"2025-02-26T07:14:39.447Z","phase":"","brief_title":"Zolbetuximab Claudin18.2 Positive, HER2 Negative, Advanced Gastric Cancer","source_id_and_acronym":"NCT06767449","lead_sponsor":"Yonsei University","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-09"},{"id":"47c94276-aadc-4f56-b0e4-df2a44de0e7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04900818","created_at":"2021-05-25T18:52:39.848Z","updated_at":"2025-02-25T14:16:01.935Z","phase":"Phase 1","brief_title":"Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04900818","lead_sponsor":"I-Mab Biopharma US Limited","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • givastomig (TJ-CD4B)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 06/29/2021","start_date":" 06/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-03"},{"id":"1f529e14-c452-4614-8462-5c41e46f432a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05231733","created_at":"2025-09-06T17:35:04.746Z","updated_at":"2025-09-06T17:35:04.746Z","phase":"Phase 1","brief_title":"Study of SPX-101 in Subjects With Advanced or Refractory Solid Tumors","source_id_and_acronym":"NCT05231733","lead_sponsor":"SparX Biotech(Jiangsu) Co., Ltd.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2024-10-31"},{"id":"42c51771-6ced-4902-9fd0-2fa649ac3732","acronym":"TranStar102","url":"https://clinicaltrials.gov/study/NCT04495296","created_at":"2021-01-18T21:32:44.326Z","updated_at":"2025-02-25T14:29:29.560Z","phase":"Phase 1/2","brief_title":"A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04495296 - TranStar102","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • gemcitabine • paclitaxel • capecitabine • oxaliplatin • osemitamab (TST001)"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 08/13/2020","start_date":" 08/13/2020","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-10-21"},{"id":"2c0cee53-ab98-4b7d-ac54-95fb9c1d1159","acronym":"8951-CL-0104","url":"https://clinicaltrials.gov/study/NCT03528629","created_at":"2021-03-09T08:59:04.304Z","updated_at":"2024-07-02T16:34:25.839Z","phase":"","brief_title":"A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma","source_id_and_acronym":"NCT03528629 - 8951-CL-0104","lead_sponsor":"Astellas Pharma Inc","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vyloy (zolbetuximab-clzb)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 05/17/2018","start_date":" 05/17/2018","primary_txt":" Primary completion: 06/09/2020","primary_completion_date":" 06/09/2020","study_txt":" Completion: 06/09/2020","study_completion_date":" 06/09/2020","last_update_posted":"2024-06-14"},{"id":"60729fe2-47ea-41ef-9371-7af88e4f8d8f","acronym":"Spotlight","url":"https://clinicaltrials.gov/study/NCT03504397","created_at":"2021-01-18T17:15:08.157Z","updated_at":"2024-07-02T16:34:27.058Z","phase":"Phase 3","brief_title":"A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer","source_id_and_acronym":"NCT03504397 - Spotlight","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 566","initiation":"Initiation: 06/21/2018","start_date":" 06/21/2018","primary_txt":" Primary completion: 09/09/2022","primary_completion_date":" 09/09/2022","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-06-11"},{"id":"9507ed2f-0466-4ed9-9e93-1955c7856ffd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065710","created_at":"2021-10-04T12:52:58.772Z","updated_at":"2024-07-02T16:35:01.207Z","phase":"Phase 1/2","brief_title":"A Study of ZL-1211 in Patients With Advanced Solid Tumor","source_id_and_acronym":"NCT05065710","lead_sponsor":"Zai Biopharmaceutical (Suzhou) Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ZL-1211"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 01/19/2022","start_date":" 01/19/2022","primary_txt":" Primary completion: 03/09/2024","primary_completion_date":" 03/09/2024","study_txt":" Completion: 04/09/2024","study_completion_date":" 04/09/2024","last_update_posted":"2024-05-24"},{"id":"a07fe804-b24b-42e5-81ce-af1dddb29fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04400383","created_at":"2021-03-09T08:59:58.256Z","updated_at":"2024-07-02T16:35:00.974Z","phase":"Phase 1","brief_title":"Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors","source_id_and_acronym":"NCT04400383","lead_sponsor":"CARsgen Therapeutics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • AB011"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 07/08/2023","primary_completion_date":" 07/08/2023","study_txt":" Completion: 09/28/2023","study_completion_date":" 09/28/2023","last_update_posted":"2024-05-24"},{"id":"493a92fd-ee54-4c1e-bd3b-4ae5fd713f00","acronym":"","url":"https://clinicaltrials.gov/study/NCT06048081","created_at":"2023-09-21T14:10:45.559Z","updated_at":"2024-07-02T16:35:01.780Z","phase":"","brief_title":"Early Access Program for Zolbetuximab","source_id_and_acronym":"NCT06048081","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-05-23"},{"id":"3e226359-22ea-4183-8dc4-9749caa27d32","acronym":"GLOW","url":"https://clinicaltrials.gov/study/NCT03653507","created_at":"2021-01-18T17:55:46.907Z","updated_at":"2024-07-02T16:35:03.022Z","phase":"Phase 3","brief_title":"A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","source_id_and_acronym":"NCT03653507 - GLOW","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative • CLDN18.2 expression","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Vyloy (zolbetuximab-clzb)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 507","initiation":"Initiation: 11/28/2018","start_date":" 11/28/2018","primary_txt":" Primary completion: 10/25/2022","primary_completion_date":" 10/25/2022","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-17"},{"id":"2f2a89e1-3f78-4f28-8767-c134a39deb5d","acronym":"ILUSTRO","url":"https://clinicaltrials.gov/study/NCT03505320","created_at":"2021-01-18T17:15:25.042Z","updated_at":"2024-07-02T16:35:04.695Z","phase":"Phase 2","brief_title":"A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma","source_id_and_acronym":"NCT03505320 - ILUSTRO","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" PD-L1 • CLDN18","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive","tags":["PD-L1 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative • CLDN18.2 expression • CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Vyloy (zolbetuximab-clzb)"],"overall_status":"Recruiting","enrollment":" Enrollment 143","initiation":"Initiation: 06/29/2018","start_date":" 06/29/2018","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-09"},{"id":"577d5037-eb6e-4785-b20b-69876702f3ed","acronym":"","url":"https://clinicaltrials.gov/study/NCT04671875","created_at":"2021-03-09T09:00:11.648Z","updated_at":"2024-07-02T16:35:14.865Z","phase":"Phase 1","brief_title":"A Clinical Study of MIL93 in Solid Tumors.","source_id_and_acronym":"NCT04671875","lead_sponsor":"Beijing Mabworks Biotech Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MIL93"],"overall_status":"Recruiting","enrollment":" Enrollment 228","initiation":"Initiation: 04/21/2021","start_date":" 04/21/2021","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-13"},{"id":"d79eae6c-ee5a-4ce6-8ddc-e1255dc5565e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05639153","created_at":"2022-12-06T15:58:04.640Z","updated_at":"2024-07-02T16:35:22.153Z","phase":"Phase 1","brief_title":"A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05639153","lead_sponsor":"Zhejiang Doer Biologics Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DR30303"],"overall_status":"Recruiting","enrollment":" Enrollment 94","initiation":"Initiation: 05/13/2022","start_date":" 05/13/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-01-25"},{"id":"c579a27c-265f-45f8-af31-1763b1f84a7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05164458","created_at":"2021-12-20T15:53:45.428Z","updated_at":"2024-07-02T16:35:24.966Z","phase":"Phase 1","brief_title":"Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies","source_id_and_acronym":"NCT05164458","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IBI-389"],"overall_status":"Recruiting","enrollment":" Enrollment 320","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2023-12-28"},{"id":"5064553d-e4ed-498f-bc5e-f6c9536a84d7","acronym":"CSG-1906-101","url":"https://clinicaltrials.gov/study/NCT05857332","created_at":"2023-05-12T17:05:01.178Z","updated_at":"2024-07-02T16:35:28.556Z","phase":"Phase 1","brief_title":"SG1906 for CLDN18.2-Positive Solid Tumors","source_id_and_acronym":"NCT05857332 - CSG-1906-101","lead_sponsor":"Hangzhou Sumgen Biotech Co., Ltd.","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SG1906"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/30/2023","start_date":" 05/30/2023","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 08/30/2025","study_completion_date":" 08/30/2025","last_update_posted":"2023-11-21"},{"id":"fb28253b-a10c-4263-9209-514e35dbc316","acronym":"","url":"https://clinicaltrials.gov/study/NCT06093425","created_at":"2023-10-23T20:13:54.880Z","updated_at":"2024-07-02T16:35:32.402Z","phase":"Phase 3","brief_title":"Combination of TST001, Nivolumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","source_id_and_acronym":"NCT06093425","lead_sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • osemitamab (TST001)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 10/31/2023","start_date":" 10/31/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-10-20"},{"id":"15c0b879-53b2-4666-8984-e56ab2ab47db","acronym":"","url":"https://clinicaltrials.gov/study/NCT06041035","created_at":"2023-09-18T15:13:15.891Z","updated_at":"2024-07-02T16:35:36.709Z","phase":"Phase 1/2","brief_title":"A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06041035","lead_sponsor":"Qilu Pharmaceutical Co., Ltd.","biomarkers":" CLDN18","pipe":"","alterations":" ","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • QLS31905"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-09-18"},{"id":"d373713b-7551-40ea-9bb5-fad8b89a9bc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06027346","created_at":"2023-09-07T16:09:46.120Z","updated_at":"2024-07-02T16:35:37.753Z","phase":"Phase 1","brief_title":"A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT06027346","lead_sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","biomarkers":" CLDN18","pipe":" | ","alterations":" CLDN18.2 expression • CLDN18.2 positive","tags":["CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CLDN18.2 expression • CLDN18.2 positive"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/17/2023","start_date":" 07/17/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-07"},{"id":"efced585-c854-448e-8e56-41b641332188","acronym":"","url":"https://clinicaltrials.gov/study/NCT05964543","created_at":"2023-07-31T17:08:45.535Z","updated_at":"2024-07-02T16:35:41.702Z","phase":"Phase 1/2","brief_title":"The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors","source_id_and_acronym":"NCT05964543","lead_sponsor":"QureBio Ltd.","biomarkers":" HER-2 • CLDN18","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • CLDN18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Q-1802"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 08/30/2025","study_completion_date":" 08/30/2025","last_update_posted":"2023-07-28"},{"id":"98a7e74d-3f89-4bec-823f-2c1fa742e162","acronym":"","url":"https://clinicaltrials.gov/study/NCT04856150","created_at":"2021-04-23T22:52:39.942Z","updated_at":"2024-07-02T16:35:41.787Z","phase":"Phase 1","brief_title":"A Study of Q-1802 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04856150","lead_sponsor":"QureBio Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Q-1802"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/21/2021","start_date":" 05/21/2021","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-07-27"}]